Pfizer beats earnings estimates as declining Covid business performs better than expected

Pfizer beats earnings estimates as declining Covid business performs better than expected


Pfizer CEO Albert Bourla talks during a press conference with European Commission President Ursula von der Leyen after a visit to oversee the production of the Pfizer-BioNtech COVID-19 vaccine at the factory of U.S. pharmaceutical company Pfizer in Puurs, Belgium April 23, 2021. 

John Thys | Reuters

Pfizer on Tuesday posted a surprise adjusted fourth-quarter profit, as the company slashed costs while demand for its Covid products plummeted.

The company reversed roughly $3.5 billion in revenue related to the expected return of 6.5 million doses of its Covid drug, Paxlovid, from the U.S. government. That hit is less than the $4.2 billion Pfizer initially expected.

The results come as Pfizer tries to blunt the rapid decline of its Covid business, which saw demand plummet to new lows and transitioned to the commercial market in the U.S. last year. 

Here’s what Pfizer reported for the fourth quarter compared to what Wall Street was expecting, based on a survey of analysts by LSEG, formerly known as Refinitiv:

  • Earnings per share: 10 cents per share adjusted vs. loss of 22 cents expected
  • Revenue: $14.25 billion vs. $14.42 billion expected

Pfizer recorded fourth-quarter revenue of $14.25 billion, down 41% from the same period a year ago, due to the plunge in sales of its Covid products.

For the fourth quarter, Pfizer booked a net loss of $3.37 billion, or 60 cents per share. That compares to a net income of $4.99 billion, or 87 cents per share, during the same period a year ago. 

Excluding certain items, the company’s posted earnings per share of 10 cents for the quarter.

The results cap a rocky year for a company that once saw revenue soar after it delivered the world’s first Covid vaccine. 

Shares of Pfizer fell roughly 40% in 2023 as demand for its shot and other Covid products plummeted worldwide, causing the company to dramatically slash its full-year revenue forecast, record multi-billion dollar charges related to inventory write-offs and launch a sweeping cost-cutting program. 

What’s more, Pfizer’s future in the booming weight loss drug market began to look bleak last month. The company scrapped a twice-daily version of its experimental weight loss pill after patients with obesity taking the drug lost significant weight but had trouble tolerating the drug in a mid-stage clinical study. 

Investors are waiting for the company to unveil data on a once-daily form of that drug, called danuglipron, during the first half of the year.

Pfizer hopes its $34 billion acquisition of cancer drugmaker Seagen, which officially closed during the fourth quarter, will restore investor confidence. Last month, the company made it clear that it was doubling down on cancer treatments after it revealed plans to create a new oncology division that includes Seagen in early 2024.

But Wall Street is still skeptical about whether Pfizer can turn things around: The company’s stock is already down more than 4% for the year, putting its market value at roughly $155 billion. 

Pfizer will hold an earnings call with investors at 10 a.m. ET on Tuesday.



Source

UnitedHealth aims to reassure investors as profits plunge, DOJ investigates its Medicare business
Health

UnitedHealth aims to reassure investors as profits plunge, DOJ investigates its Medicare business

Omar Marques | Lightrocket | Getty Images UnitedHealth Group Chairman and CEO Stephen Hemsley will face the first real test Tuesday of his ability to regain investor confidence as the largest private U.S. insurer reports earnings. The Dow component has seen its share price cut nearly in half since mid-May, with the stock on pace […]

Read More
UnitedHealth says it is cooperating with DOJ investigation into Medicare billing practices
Health

UnitedHealth says it is cooperating with DOJ investigation into Medicare billing practices

The UnitedHealth logo on a laptop arranged in New York, US, on Friday, July 7, 2023. Gabby Jones | Bloomberg | Getty Images UnitedHealth Group revealed Thursday it is facing a Justice Department investigation over its Medicare billing practices, adding to a string of setbacks for a company that owns the nation’s largest and most […]

Read More
Healthy Returns: Researchers move closer to a universal cancer vaccine
Health

Healthy Returns: Researchers move closer to a universal cancer vaccine

Wildpixel | Istock | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. A universal cancer vaccine – what once seemed like a pipe dream – may be inching closer to becoming reality.  On […]

Read More